Sempresto, Inc., a company developing a next-generation platform for smartphone-integrated rescue medications, today announced that it has been featured in a recent Inc. article by Chloe Capital, highlighting Alerje and its innovative approach to improving access to life-saving treatment for individuals with severe allergies.

The article underscores the origins of Alerje’s technology, which, like Sempresto’s, was developed to address real-world challenges faced by patients and caregivers managing anaphylaxis risk. Sempresto’s recent acquisition of Alerje’s autoinjector platform builds upon its two prior platform acquisitions and expanded the company’s IP portfolio, advancing its mission to modernize how rescue medications are carried, accessed, and administered in critical moments.

“We are honored to see Alerje’s story recognized and to carry forward the important work behind its technology,” said Elizabeth (Liz) Reczek, PhD, CEO and Co-Founder of Sempresto. “This acquisition reflects our commitment to developing intuitive, accessible solutions that better align with how patients live their daily lives.”

The Inc. feature highlights the growing momentum behind patient-centered innovation in emergency medicine and the role of mission-driven founders in shaping the future of care. This recognition comes shortly after Sempresto was awarded first place in the 2026 Girls Into VC pitch competition at Harvard University, reflecting the strong interest in and need for the Company’s platform and its potential to improve access to life-saving treatment.

Read the full article:

https://www.inc.com/elisa-miller-out/founder-javier-evelyn-alerje-sempresto-food-allergies-lifesaving-startup-chloe-capital/91317659

About Sempresto, Inc.

Sempresto, Inc. is a medical device company led by a team of biotech and medical technology experts, many with firsthand experience managing severe allergies. Guided by its mission, “Always There, Always Connected,” Sempresto is committed to ensuring immediate access to life-saving treatments. The company’s flagship product, a smartphone-integrated epinephrine autoinjector, represents a transformative step forward in emergency preparedness and patient empowerment.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260319706962/en/